News & Updates

GSK’s Successful Launch of Sensodyne Repair and Protect Deep Repair

Tooth sensitivity is a clinically important problem that affects a considerable proportion of the adult population. It can exert significant burden on patients and may largely affect their quality of life which highlights the need for effective solutions against dentine hypersensitivity. However, the limitations that the COVID pandemic has brought about has greatly altered patients’ health-seeking behavior and ultimately, the dynamics of the relationship between dentists and their patients. As such, there is a need for novel solutions that patients can rely on to effectively address dentine hypersensitivity.

ACOG article 2.7

Treatment with fezolinetant significantly reduced the frequency and severity of vasomotor symptoms (VMS), particularly hot flashes, in women during their menopausal phase, according to the SKYLIGHT 1* trial presented at ACOG 2022.

Debunking the myths about DPP-4 inhibitors

Navigating the evolving landscape of diabetes management requires precise knowledge. In this exploration into the world of DPP-4 inhibitors (DPP4is), we aim to debunk prevalent myths and provide nuanced insights.

Product Highlight - MENQUADFI

Meningococcal group A, C, W & Y conjugate vaccine 0.5 mL solution for injection

Product Highlight - LYPSTAPLUS

Rosuvastatin + Ezetimibe 10/10 mg and 20/10 mg film-coated tablet

Treatment advances in relapsed/refractory large B-cell lymphoma

Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive subtype of non-Hodgkin’s lymphoma. Despite a high success rate associated with first-line immunochemotherapy, approximately 40% of patients relapse or demonstrate resistance to treatment, significantly reducing life expectancy.¹

Nirmatrelvir reduces the risk of long COVID

Post-COVID condition, also known as long COVID, is a serious public health problem affecting millions of people around the world.¹

Death, adverse health outcomes higher for COVID-19 than influenza after hospital admission

Robust evidence for fenofibrate in patients with metabolic syndrome on statins

Treating type 2 diabetes mellitus with G.R.A.C.E.

A challenging aspect of glycaemic control presents in patients diagnosed with early-onset type 2 diabetes mellitus (T2DM). Considering this challenge, how can effective management of glycaemic control be achieved in patients with uncontrolled T2DM who are hesitant to incorporate multiple oral antidiabetic drugs into their current regimen? In this case study, Dr Matthew Tan shared his clinical experience in managing a young adult patient with T2DM using GLYXAMBI^®, a fixed-dose combination of empagliflozin and linagliptin taken once daily. He demonstrated how applying the G.R.A.C.E. concept to the treatment improved the patient’s clinical outcome.

This advertorial is sponsored as an educational programme by Boehringer Ingelheim Singapore Pte. Ltd.